The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors.

Archive ouverte

Gall, G. L. | Cherifi, F. | Divoux, J. | Florent, R. | Christy, F. | Leconte, A. | San, C. | Devillers, A. | Desmartin, G. | Lecouflet, L. | Clarisse, B. | Ballesta, S. | Thorel, L. | Dubois, B. | Harter, V. | Rousseau, N. | Gaichies, L. | Martin-Françoise, S. | Le Brun, J. F. | Dolivet, E. | Rouzier, R. | Jeanne, C. | Blanc-Fournier, C. | Figeac, Martin | Leman, R. | Castera, L. | Poulain, L. | Weiswald, Louis-Bastien | Joly, Florence

Edité par CCSD ; BioMed Central -

International audience. BackgroundCombination of chemotherapy and immunotherapy is the current standard of care for advanced endometrial cancer. However, survival outcome remains poor, highlighting the urgent need for new treatments and reliable tools to identify patients who will benefit from them. Patient-Derived Tumor Organoids (PDTO) are three-dimensional structures established from patient tumors, and are closely mimicking the features of the tumor of origin. Moreover, more and more evidences show that PTDOs hold promises as predictive tools for the response to treatment of patients.MethodThe PENDOR study is a monocentric observational study designed to assess the feasibility of generating and testing PDTOs derived from endometrial cancer for evaluating treatment sensitivity. PDTOS will be established from surgical specimens not required for anatomopathological diagnosis. Tumor cells will be dissociated, embedded in extracellular matrix, and cultured in a medium supplemented with growth factors and signaling pathways inhibitors. Molecular and histological analyses will be conducted to validate the resemblance of PDTO to the original tumor. Response of PDTO to conventional chemotherapy and PARP inhibitors will be evaluated and compared to clinical response and to the results of an academic HRD test Genomic Instability Scar (GIScar), respectively, to assess their predictive value.DiscussionThis pilot study aims to validate the feasibility to develop PDTOs from endometrial cancer from patients who will undergo surgical resection. We aim to provide a proof of concept regarding the predictive value of these models for their potential application into routine clinical practice as part of precision medicine. This approach could therefore facilitate the identification of patients who could benefit from PARP inhibitors.

Suggestions

Du même auteur

The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers

Archive ouverte | Thorel, L. | CCSD

International audience. BackgroundOvarian cancer is the first cause of death from gynecological malignancies mainly due to development of chemoresistance. Despite the emergence of PARP inhibitors, which have revolut...

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.

Archive ouverte | Divoux, J. | CCSD

International audience. BackgroundTriple negative breast cancers (TNBC) account for approximately 15% of all breast cancers and are associated with a shorter median survival mainly due to locally advanced tumor and ...

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.

Archive ouverte | Thorel, L. | CCSD

International audience. BackgroundIn the era of personalized medicine, the establishment of preclinical models of cancer that faithfully recapitulate original tumors is essential to potentially guide clinical decisi...

Chargement des enrichissements...